CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Inactivated SARS-CoV-2 Vaccine (Vero cell)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2122 Placebo Wiki 0.04

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.06
D007239 Infection NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above

This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.

NCT04510207 COVID-19 Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Biological: Placebo

Primary Outcomes

Measure: The incidence of COVID-19 cases after two-doses of vaccination

Time: From14 days after the second dose to 6 month after the second dose

Secondary Outcomes

Measure: The incidence of severe cases of SARS-CoV-2 pneumonia and deaths accompanied by COVID-19 after two-doses of vaccination

Time: From14 day after the second dose to 6 month after the second dose

Measure: The incidence of any adverse reactions/events

Time: 28 days after each immunization

Measure: The incidence of serious adverse events (SAE)

Time: From the beginning of the first dose to 12 months after the second immunization

Measure: The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody

Time: 14 days after full course of immunization

Measure: The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody

Time: 14 days after full course of immunization

Measure: The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody

Time: 14 days after full course of immunization

Measure: The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody

Time: 28 days, 3rd month, 6th month, 9th month, and 12th month after 2 doses of immunization

Measure: The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody

Time: 28 days, 3rd month, 6th month, 9th month, and 12th month after 2 doses of immunization

Measure: The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody

Time: 28 days, 3rd month, 6th month, 9th month, and 12th month after 2 doses of immunization

Other Outcomes

Measure: the anti-SARS-CoV-2 neutralizing antibody protective level against COVID-19

Time: 14 days after 2 doses of vaccination

Measure: The occurrence of ADE

Time: From the beginning of the first dose to 12 months after the second immunization

2 Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above

This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.

NCT04510207 COVID-19 Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Biological: Placebo

Primary Outcomes

Measure: The incidence of COVID-19 cases after two-doses of vaccination

Time: From14 days after the second dose to 6 month after the second dose

Secondary Outcomes

Measure: The incidence of severe cases of SARS-CoV-2 pneumonia and deaths accompanied by COVID-19 after two-doses of vaccination

Time: From14 day after the second dose to 6 month after the second dose

Measure: The incidence of any adverse reactions/events

Time: 28 days after each immunization

Measure: The incidence of serious adverse events (SAE)

Time: From the beginning of the first dose to 12 months after the second immunization

Measure: The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody

Time: 14 days after full course of immunization

Measure: The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody

Time: 14 days after full course of immunization

Measure: The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody

Time: 14 days after full course of immunization

Measure: The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody

Time: 28 days, 3rd month, 6th month, 9th month, and 12th month after 2 doses of immunization

Measure: The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody

Time: 28 days, 3rd month, 6th month, 9th month, and 12th month after 2 doses of immunization

Measure: The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody

Time: 28 days, 3rd month, 6th month, 9th month, and 12th month after 2 doses of immunization

Other Outcomes

Measure: the anti-SARS-CoV-2 neutralizing antibody protective level against COVID-19

Time: 14 days after 2 doses of vaccination

Measure: The occurrence of ADE

Time: From the beginning of the first dose to 12 months after the second immunization

No related HPO nodes (Using clinical trials)